Companies / Japan
Merck & Co Tests Januvia, Amid 'Drug Lag' Concerns
August 2006 | Market Trend AnalysisUS drug major Merck & Co has begun trials in Japan for its novel antibiabetic sitagliptin, branded in global markets as Januvia. The orally administered drug, a first-in-class dipeptidyl peptidase-IV inhibitor, represents an advance in blood glucose regulation therapies. Januvia recently received its first marketing authorisation in
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
